Results 201 to 210 of about 396,260 (312)

In-bedroom renewed air as anti-inflammatory adjuvant therapy in cancer survivors: protocol for the randomised, placebo-controlled BREATHS N-of-1 trial series. [PDF]

BMJ Open
Hernandez-Garcia E, Edkins A, Chrysikou E, Ordóñez-Mena JM, Nekhlyudov L, Kim JB, McLean GR, Frost H, Panigrahy D.   +8 more
europepmc   +1 more source

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

Arthritis &Rheumatology, Accepted Article.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week (W), double‐blind, placebo‐controlled, phase 3 POETYK PsA‐2 study
Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze‐Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar   +20 more
wiley   +1 more source

Counterfeit <i>Citri Reticulatae Pericarpium</i> Identification: Multi-Class Detection Using Vis/NIR Spectroscopy and Residual Neural Networks. [PDF]

Food Sci Nutr
Ma C, Zhang M, Ma J, Chen S, Yuan Y, Du M, Dai Z.   +6 more
europepmc   +1 more source

Anti‐carbamylated fibrinogen autoantibodies of IgG and IgA isotypes contribute to a better prognostic stratification in very early rheumatoid arthritis: data from the French national ESPOIR cohort

Arthritis &Rheumatology, Accepted Article.
Objective To investigate the prevalence and longitudinal evolution of anti‐carbamylated fibrinogen antibodies (ACa‐Fib) of IgG and IgA isotypes in early rheumatoid arthritis (RA), and determine whether these antibodies provide additional diagnostic and prognostic information beyond anti‐cyclic citrullinated peptide antibodies (anti‐CCP) and rheumatoid ...
Pauline Brevet, Olivia Guérin, Léna Le Goaréguer, Élisa Halbourg, Marie‐Laure Golinski, Sophie Candon, Olivier Boyer, Thierry Lequerré, Thierry Schaeverbeke, Valérie Devauchelle‐Pensec, Olivier Vittecoq, Manuel Fréret   +11 more
wiley   +1 more source

Feasibility of C-reactive protein point-of-care testing for antibiotic stewardship in rural GP-pharmacy settings. [PDF]

Antimicrob Steward Healthc Epidemiol
Saha SK, Muleme M, Hecke OV, Chatterton ML, Athan E.   +4 more
europepmc   +1 more source

Navigating adverse immunostimulation: A practical guide for clinical researchers

British Journal of Clinical Pharmacology, EarlyView.
Problem Setting As drug development moves towards more complex products, early clinical development programmes are increasingly hampered by unwanted and/or unexpected activation of the immune system (adverse immune stimulation, AIS). Solution At the Centre for Human Drug Research, we have introduced standardized procedures to make AIS manageable, while
Juliette A. van den Noort, Anouk C. Meijs, Naomi B. Klarenbeek, Matthijs Moerland   +3 more
wiley   +1 more source

CRP Is a Key Indicator of Rheumatoid Arthritis-Associated Vascular Injury and Neurodegeneration. [PDF]

Int J Mol Sci
Lazarut-Nistor A, Sibianu M, Slevin M.
europepmc   +1 more source

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

British Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort, Marella C. E. van Ruissen, Lisanne C. A. Smidt, Naomi B. Klarenbeek, Philip H. K. Kremer, Manon A. A. Jansen, Jacobus Burggraaf, Joop M. A. van Gerven, Matthijs Moerland   +8 more
wiley   +1 more source

Pentoxifylline dose finding trial in preterm neonates with suspected late onset sepsis (PTX‐trial)

British Journal of Clinical Pharmacology, EarlyView.
Aim The aim of this study (PTX‐trial) is to determine the optimal dose of pentoxifylline (PTX) in preterm neonates (gestational age < 30 weeks) with (suspected) late onset sepsis (LONS). Methods The PTX‐trial is a prospective multicentre open‐label sequential dose‐optimization study with an adapted continual reassessment method.
Serife Kurul, H. Rob Taal, Jan Mazela, Ryszard Lauterbach, Irwin K. M. Reiss, Karel Allegaert, Robert B. Flint, Sinno H. P. Simons   +7 more
wiley   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source